Orexo
Develops pharmaceuticals and digital therapies for substance use and mental health.
ORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000736415 (+2 more)
- LEI:
- 549300LJ5CCWDPTK9Z08
- Country:
- Sweden
- Address:
- Box 303, 751 05 UPPSALA
- Website:
- https://orexo.com/
- Sector:
- Manufacturing
Description
Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2012-01-31 08:31 | Swedish | 427.7 KB | |||
| 2012-01-31 08:31 | English | 432.1 KB | |||
| 2012-01-31 08:30 |
Orexos forskningssamarbete avslutas och OX-CLI-/ OX-ESI-projekten läggs ned
|
Swedish | 46.0 KB | ||
| 2012-01-31 08:30 |
Orexo’s drug discovery collaboration terminated and OX-CLI/OX-ESI projects end
|
English | 43.1 KB | ||
| 2011-12-20 13:00 |
Positiva studieresultat för OX27
|
Swedish | 96.8 KB | ||
| 2011-12-20 13:00 |
Positive study results for OX27
|
English | 97.3 KB | ||
| 2011-11-30 08:00 |
Orexo och Uppsala universitet får Vetenskapsrådets anslag för keramprojekt
|
Swedish | 114.6 KB | ||
| 2011-11-30 08:00 |
Orexo and Uppsala University receive Swedish Research Council grant for biocera…
|
English | 113.9 KB | ||
| 2011-11-09 08:00 | Swedish | 1.0 MB | |||
| 2011-11-09 08:00 | English | 1.2 MB | |||
| 2011-10-11 08:00 |
Valberedning inför Orexos årsstämma 2012 och finansiell kalender 2011/2012
|
Swedish | 126.1 KB | ||
| 2011-10-11 08:00 |
Nomination Committee prior to Orexo’s Annual General Meeting 2012 and Financial…
|
English | 112.1 KB | ||
| 2011-10-04 09:00 |
Orexo utser Peter Edman till chef för forskning och utveckling
|
Swedish | 104.1 KB | ||
| 2011-10-04 09:00 |
Orexo appoints Peter Edman as Chief Scientific Officer
|
English | 104.9 KB | ||
| 2011-09-21 08:00 |
Orexo announces positive results supporting OX219 for treatment of opioid depen…
|
English | 128.9 KB |
Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Orexo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Orexo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-11 | Nikolaj Arrild Sørensen | Other | Buy | 2,460 | 35,178.00 SEK |
| 2025-04-04 | Nikolaj Arrild Sørensen | Other | Buy | 3,500 | 47,530.00 SEK |
| 2024-03-26 | Fredrik Järrsten | Other | Buy | 3,000 | 44,040.00 SEK |
| 2023-11-24 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 44,640.00 SEK |
| 2023-11-08 | Fredrik Järrsten | Other | Buy | 1,500 | 23,715.00 SEK |
| 2023-02-24 | Nikolaj Arrild Sørensen | Other | Buy | 11,500 | 188,945.00 SEK |
| 2023-01-27 | Fredrik Järrsten | Other | Buy | 4,500 | 79,695.00 SEK |
| 2022-07-26 | Michael Matly | Other | Buy | 2,820 | 60,777.77 SEK |
| 2022-07-21 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 61,500.00 SEK |
| 2022-07-15 | James Noble | Other | Buy | 18,500 | 394,252.80 SEK |
Peer Companies
